随着预防性疫苗和肿瘤治疗两大mRNA主赛道日益成熟，全球mRNA产业正急需拓展新的技术方向和商业空间。相比疫苗与肿瘤治疗通常面临的突变抗原和免疫逃逸问题，自身免疫病中相对稳定的自身抗原靶点，使其天然适配mRNA诱导免疫耐受的机制。

具有免疫耐受性的抗原呈递细胞（APC）有望成为治疗自身免疫疾病中抑制 T 细胞活化的疗法。然而，患者自体抗原呈递细胞的分离和体外操作成本高昂，而且这一过程需要为每位患者进行量身定制。

近日，中国科学技术大学生物医学工程学院王育才教授课题组通过体内筛选优化得到的低免疫原性LNPs，成功在体内直接编程生成耐受性抗原呈递细胞（tol-APCs），治疗自身免疫性疾病（AIDs）。相关研究成果以“Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 ...

Supercharged immunity solves ‘last-mile’ vaccine delivery challenge that could transform battles against cancer, pandemics, ...

Traditional vaccines work by stimulating the immune system, but their effectiveness is often limited by how well they can ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

With every bite of food we take, our intestinal immune system must make a big decision. Tasked with defending us from foreign pathogens, these exquisitely sensitive cells somehow distinguish friend ...

With every bite of food we take, our intestinal immune system must make a big decision. Tasked with defending us from foreign pathogens, these exquisitely sensitive cells somehow distinguish friend ...

China has introduced a groundbreaking vaccine booster, reportedly enhancing immune responses to cancer and infections by up ...

Single-cell characterization of healthy fallopian tubes revealed shifts in cell and gene expression throughout the menstrual ...

Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...